Atypical neuromuscular disease characteristics associated with anti-programmed cell death protein 1


  • Neuromuscular-related adverse events (AEs) associated with programmed cell death protein 1 (PD-1) treatment for cancer may be incorrectly diagnosed in 20% of cases, therefore thorough neurological and laboratory assessments are necessary.

Why this matters

  • Patients with cancer are increasingly being prescribed immune checkpoint inhibitors such as PD-1; greater understanding is needed of neuromuscular immune-related AEs, which may affect <7.7% patients.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.